Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study

This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.

本研究旨在对比三种剂量的司美格鲁肽（semaglutide）在正在服用二甲双胍的2型糖尿病（type 2 diabetes, T2D）合并超重受试者中的疗效。研究主要考察受试者在使用不同剂量的研究药物时，其血糖与体重的控制效果。受试者将被分配接受司美格鲁肽[2毫克(mg)、8 mg或16 mg]或司美格鲁肽安慰剂（模拟药物）。研究药物将通过名为NovoPen®4的注射笔给药，该注射笔为带有针头的皮下注射医用工具。本研究周期约为52周，受试者需完成13次门诊随访及4次电话随访。